Mometasone furoate: An inhaled glucocorticoid for the management of asthma in adults and children

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 12, 2009, Pages 2009-2014

  Cowie, Robert L ^a   Giembycz, Mark A ^b   Leigh, Richard ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Administration; Adrenal cortex hormones; Adult; Adverse effects; Antiasthmatic agents; Asthma; Children; Drug therapy; Glucocorticoids; Inhalation; Receptors; Review; Steroid

Indexed keywords

BECLOMETASONE; BUDESONIDE; CORTICOSTEROID; DEXAMETHASONE; FLUNISOLIDE; FLUTICASONE PROPIONATE; FORMOTEROL; GLUCOCORTICOID; INDACATEROL; MOMETASONE FUROATE; PLACEBO; STEROID; TRIAMCINOLONE;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DYSPHONIA; EVENING DOSAGE; GLAUCOMA; GROWTH INHIBITION; HUMAN; HYDROCORTISONE BLOOD LEVEL; METERED DOSE INHALER; MORNING DOSAGE; OROPHARYNX CANDIDIASIS; POWDER INHALER; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADULT; ANTI-ALLERGIC AGENTS; ASTHMA; BIOLOGICAL AVAILABILITY; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOCORTICOIDS; HUMANS; PREGNADIENEDIOLS;

EID: 68149179477     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903078428     Document Type: Review

References (57)

1. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469-478
2. Global Initiative on Asthma (GINA). Global strategy for asthma management and prevention: NHLBI/WHO Workshop Report. Bethesda: National Institutes of Health, National Heart, Lung and Blood Institute, 2006
3. Kelly HW. Pharmaceutical characteristics that influence the clinical efficacy of inhaled corticosteroids. Ann Allergy Asthma Immunol 2003;91:326-334
4. Bateman ED, Clark TJ, Frith L, et al. Rate of response of individual asthma control measures varies and may overestimate asthma control: an analysis of the Goal study. J Asthma 2007;44:667-673 (Pubitemid 47621477)
5. Ward C, Pais M, Bish R, et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 2002;57:309-316 (Pubitemid 34298927)
6. Inman MD, Watson RM, Rerecich T, et al. Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am J Respir Crit Care Med 2001;164:569-574 (Pubitemid 32801658)
7. Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 2002;165:1377-1383
8. Affrime MB, Cuss F, Padhi D, et al. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol 2000;40:1227-1236 (Pubitemid 30818312)
9. Derendorf H, Daley-Yates PT, Pierre LN, Efthimiou J. Bioavailability and metabolism of mometasone furoate: pharmacology versus methodology. J Clin Pharmacol 2002;42:383-387 (Pubitemid 34259771)
10. Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax 2000;55:603-613
11. Issar M, Sahasranaman S, Buchwald P, Hochhaus G. Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Respir J 2006;27:511-516 (Pubitemid 43372524)
12. Bledsoe RK, Montana VG, Stanley TB, et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 2002;110:93-105
13. Bledsoe RK, Stewart EL, Pearce KH. Structure and function of the glucocorticoid receptor ligand binding domain. Vitam Horm 2004;68:49-91 (Pubitemid 39753677)
14. Leo JC, Guo C, Woon CT, et al. Glucocorticoid and mineralocorticoid cross-talk with progesterone receptor to induce focal adhesion and growth inhibition in breast cancer cells. Endocrinology 2004;145:1314-1321 (Pubitemid 38281015)
15. Grossmann C, Scholz T, Rochel M, et al. Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol 2004;151:397-406 (Pubitemid 39307329)
16. Austin RJ, Maschera B, Walker A, et al. Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J 2002;20:1386-1392 (Pubitemid 35460605)
17. Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol 2007;293:L660-7 (Pubitemid 47358828)
18. Tayab ZR, Fardon TC, Lee DK, et al. Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. Br J Clin Pharmacol 2007;64:698-705
19. Fardon TC, Lee DK, Haggart K, et al. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med 2004;170:960-966 (Pubitemid 39425691)
20. Roumestan C, Henriquet C, Bousquet J, Mathieu M. Fluticasone propionate and mometasone furoate have equivalent transcriptional potencies. Clin Exp Allergy 2003;33:895-901 (Pubitemid 36851237)
21. Valotis A, Hogger P. Significant receptor affinities of metabolites and a degradation product of mometasone furoate. Respir Res 2004;5:7 (Pubitemid 41358088)
22. Sahasranaman S, Issar M, Hochhaus G. Metabolism of mometasone furoate and biological activity of the metabolites. Drug Metab Dispos 2006;34:225-233 (Pubitemid 43145024)
23. Crim C, Pierre LN, Daley-Yates PT. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther 2001;23:1339-1354 (Pubitemid 32912787)
24. Chapman RW, Sehring SJ, Garlisi CG, et al. Anti-inflammatory activity of inhaled mometasone furoate in allergic mice. Arzneimittelforschung 1998;48:384-391
25. Berger WE, Milgrom H, Chervinsky P, et al. Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma. Ann Allergy Asthma Immunol 2006;97:672-680 (Pubitemid 44851467)
26. Meltzer E, Baena-Cagnani C, Chervinsky P, et al. Once-daily mometasone furoate administered by dry powder inhaler for the treatment of children with persistent asthma. Ped Asthma Allerg Immunol 2007;20:83-92 (Pubitemid 47325098)
27. Amirav I, Newhouse MT, Mansour Y. Measurement of peak inspiratory flow with in-check dial device to simulate low-resistance (Diskus) and high-resistance (Turbohaler) dry powder inhalers in children with asthma. Pediatr Pulmonol 2005;39:447-451 (Pubitemid 40548287)
28. Yang TT, Li S, Wyka B, Kenyon D. Drug delivery performance of the mometasone furoate dry powder inhaler. J Aerosol Med 2001;14:487-494
29. Bentur L, Mansour Y, Hamzani Y, et al. Measurement of inspiratory flow in children with acute asthma. Pediatr Pulmonol 2004;38:304-307 (Pubitemid 39245112)
30. Kamps AW, Brand PL, Roorda RJ. Variation of peak inspiratory flow through dry powder inhalers in children with stable and unstable asthma. Pediatr Pulmonol 2004;37:65-70
31. Bousquet J. Mometasone furoate: an effective anti-inflammatory with a well-defined safety and tolerability profile in the treatment of asthma. Int J Clin Pract 2009;63:806-819
32. Bernstein DI, Berkowitz RB, Chervinsky P, et al. Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med 1999;93:603-612 (Pubitemid 29476249)
33. Bousquet J, D'Urzo A, Hebert J, et al. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. Eur Respir J 2000;16:808-816 (Pubitemid 32049364)
34. O'Connor B, Bonnaud G, Haahtela T, et al. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Ann Allergy Asthma Immunol 2001;86:397-404 (Pubitemid 32332318)
35. Carlsson LG, Edsbacker S. Comparative efficacy and safety of mometasone furoate dry powder inhaler and budesonide Turbuhaler. Eur Respir J 2001;17:1332-1333 (Pubitemid 32717496)
36. Derendorf H, Daley-Yates PT, Pierre LN, Efthimiou J. Systemic bioavailability of inhaled steroids: the importance of appropriate and comparable methodology. Eur Respir J 2001;17:157-158 (Pubitemid 32600571)
37. Lipworth BJ. Mometasone furoate levels. Chest 2001;120:1034-1035
38. Sharpe M, Jarvis B. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs 2001;61:1325-1350 (Pubitemid 32744413)
39. Fish JE, Karpel JP, Craig TJ, et al. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J Allergy Clin Immunol 2000;106:852-860
40. Nayak AS, Banov C, Corren J, et al. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann Allergy Asthma Immunol 2000;84:417-424 (Pubitemid 30226977)
41. Kemp JP, Berkowitz RB, Miller SD, et al. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol 2000;106:485-492
42. Noonan M, Karpel JP, Bensch GW, et al. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Ann Allergy Asthma Immunol 2001;86:36-43 (Pubitemid 32104568)
43. Corren J, Berkowitz R, Murray JJ, Prenner B. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. Int J Clin Pract 2003;57:567-572 (Pubitemid 37185067)
44. Wardlaw A, Larivee P, Eller J, et al. Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate. Ann Allergy Asthma Immunol 2004;93:49-55 (Pubitemid 39243135)
45. Chrousos GP, Ghaly L, Shedden A, et al. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects. Chest 2005;128:70-77 (Pubitemid 40994456)
46. Mortimer KJ, Harrison TW, Tang Y, et al. Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma. Br J Clin Pharmacol 2006;62:412-419 (Pubitemid 44401524)
47. Bernstein DI, Allen DB. Evaluation of tests of hypothalamic-pituitary- adrenal axis function used to measure effects of inhaled corticosteroids. Ann Allergy Asthma Immunol 2007;98:118-127
48. Mortimer KJ, Harrison TW, Tattersfield AE. Effects of inhaled corticosteroids on bone. Ann Allergy Asthma Immunol 2005;94:15-21
49. Leone FT, Fish JE, Szefler SJ, West SL. Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma: collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and Immunology. Chest 2003;124:2329-2340
50. Garrott HM, Walland MJ. Glaucoma from topical corticosteroids to the eyelids. Clin Experiment Ophthalmol 2004;32:224-226
51. Breton MC, Beauchesne MF, Lemiere C, et al. Risk of perinatal mortality associated with asthma during pregnancy. Thorax 2009;64:101-106
52. NAEEP Expert Panel Report. Expert Panel Report 3 (EPR-3): guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol 2007;120(5 Suppl):S94-138
53. Bensch GW, Prenner B, Berkowitz R, et al. Once-daily evening administration of mometasone furoate in asthma treatment initiation. Ann Allergy Asthma Immunol 2006;96:533-540
54. D'Urzo A, Karpel JP, Busse WW, et al. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. Curr Med Res Opin 2005;21:1281-1289 (Pubitemid 41140732)
55. Karpel JP, Busse WW, Noonan MJ, et al. Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma. Ann Pharmacother 2005;39:1977-1983
56. Beeh KM, Derom E, Kanniess F, et al. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J 2007;29:871-878 (Pubitemid 46711890)
57. Calverley PM, Rennard S, Nelson HS, et al. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir Res 2008;9:73